Emphasis on Treatment Type (Prophylactic, Therapeutic), Route of Administration (Oral, Injectable), Distribution Channel (Hospital Pharmacies, Community Health Centers, Retail Pharmacies and Online); and Region/Country
The Mpox Treatment Market was valued at approximately USD 1,025.46 million in 2023 and is expected to grow at a substantial CAGR of around 10.86% during the forecast period (2024-2032) owing to the rise in prevalence of mpox, technological advancement, and increased focus on preventive measures.
Mpox also previously referred to as monkeypox, is an infectious disease in humans, caused by the monkeypox virus which belongs to the Orthopoxvirus species. The primary mode of transmission is directly through person to person touching or respiratory droplets produced when the patient with the disease coughs or sneezes. The disease can also be transmitted through materials and animals to human beings, especially from areas such as some parts of Central and West Africa.
According to WHO, In May 2022, an outbreak of mpox appeared suddenly and rapidly spread across Europe, the Americas and then all six WHO regions. WHO states that, since 2022, there has also been an upsurge in mpox cases and deaths in the Democratic Republic of Congo. As of 30 September 2024, a total of 1,09,699 laboratory-confirmed cases, including 236 deaths, have been reported to WHO. As of September 2024, the number of monthly reported new cases has increased by 8%, compared to the previous month. The majority of the cases reported in the past month were notified from the African Region (63.6%) and the Region of the Americas (15.5%). The 10 most affected countries globally since 1 January 2022 are the United States of America (n = 34,063), Brazil (n = 12,722), Spain (n = 8,282), Democratic Republic of the Congo (n = 7 ,095), France (n = 4,334), Colombia (n = 4,269), Mexico (n = 4,177), The United Kingdom (n = 4,100), Peru (n = 3,948), and Germany (n = 3,932). Together, these countries account for 79.2% of the cases reported globally.
This section discusses the key market trends influencing the various segments of the mpox treatment market as identified by our research experts.
Frequent and continuous collaborations and partnerships are among the most essential trends for the growth of the Mpox treatment market. Partnership agreements between pharmaceutical companies and research organizations gain expertise from each other and allow access to the latest technologies that help in the development of advanced and innovative therapeutics to combat mpox. Mergers and acquisitions allow the key players to gain access to a new geography and ensure market expansion as well as enhance their global reach. For instance, in September 2023, BioNTech SE and the Coalition for Epidemic Preparedness Innovations (CEPI) announced a strategic partnership to advance mRNA-based vaccine candidates with the development of BNT166 for the prevention of mpox. Through this partnership, CEPI will provide funding of up to $90 million to support the development of mRNA-based vaccine candidates.
North America has the most significant dominance in the global mpox treatment market due to the development of its healthcare sector and efficient precautionary measures against the disease. With growing cases of mpox in the region, North America is expected to grow rapidly in the next few years. Furthermore, the increasing healthcare spending across the region creates a better outcome in relation to infrastructure that makes antiviral medications and vaccines easily accessible. Altogether, these factors help to build a stable background for the establishment of therapeutics and vaccines for the treatment of Mpox, which, in due course, should contribute to a decrease in the negative influences of this infectious disease on public health. Additionally, the accessibility of therapeutics in the region further creates growth for this market. For instance, in April 2024, Bavarian Nordic A/S announced that JYNNEOS®, the only FDA-approved mpox vaccine, is now commercially available in the U.S., marking a significant expansion for access to JYNNEOS® by establishing additional pathways for vaccine procurement, distribution, and reimbursement by both public and private payers.
The mpox treatment market is competitive, with several global and international players. The key players are adopting different growth strategies to enhance their market presence, such as partnerships, agreements, collaborations, new product launches, geographical expansions, and mergers and acquisitions. Some of the major players operating in the market are Bavarian Nordic A/S, SIGA Technologies, Inc., Tonix Pharmaceuticals Holding Corp., BioNTech SE., Emergent BioSolutions Inc., GeoVax Labs, Inc., Gilead Sciences, Inc., KM Biologics Co., Ltd., Moderna, Coalition for Epidemic Preparedness Innovations (“CEPI”).
In September, 2024- Bavarian Nordic A/S announced an agreement with UNICEF for the supply of 1 million doses of the MVA-BN® mpox vaccine for countries in Africa impacted by the mpox outbreak. Under the agreement, UNICEF will procure 1 million doses of the vaccine which includes the 500,000 doses that were committed by Gavi. The company will prioritize increasing its production capacity to fulfil the short- and medium-term demand.
In October, 2024- SIGA Technologies, Inc., which is a commercial-stage pharmaceutical company and leader in infectious diseases, announced that it has entered into an agreement with Vanderbilt University to obtain a license to a portfolio of preclinical fully human monoclonal antibodies (mAbs) which could be used as potential treatments for a broad range of orthopoxviruses, including smallpox and mpox. Under the agreement, SIGA has exercised its option to license the exclusive rights to develop, manufacture, and commercialize these mAbs globally.
In April, 2024- SIGA Technologies, Inc. announced that it has entered into an amendment to its international promotion agreement with Meridian Medical Technologies, Inc. (Meridian). According to this agreement, SIGA will drive international promotion activities for oral TPOXX® while maintaining its contractual relationship with Meridian to maintain continuity for key customer relationships.
Details | |
Base year | 2023 |
Forecast period | 2024-2032 |
Growth momentum | Accelerate at a CAGR of 10.86% |
Market size 2023 | USD 1,025.46 million |
Regional analysis | North America, Europe, Asia-Pacific, Rest of the World |
Major contributing region | Asia-Pacific is expected to grow at the highest CAGR during the forecasted period. |
Key countries covered | U.S., Canada, Germany, France, UK, Spain, Italy, China, Japan, and India |
Bavarian Nordic A/S, SIGA Technologies, Inc., Tonix Pharmaceuticals Holding Corp., BioNTech SE., Emergent BioSolutions Inc., GeoVax Labs, Inc., Gilead Sciences, Inc., KM Biologics Co., Ltd., Moderna, Coalition for Epidemic Preparedness Innovations (“CEPI”) | |
Report Scope | Market Trends, Drivers, and Restraints; Revenue Estimation and Forecast; Segmentation Analysis; Demand and Supply Side Analysis; Competitive Landscape; Company Profiling |
Segments Covered | By Treatment type, By Route of administration, By Distribution channel, By Region/Country |
The study includes market sizing and forecasting analysis validated by authenticated key industry experts.
The report presents a quick review of overall industry performance at one glance.
The report covers an in-depth analysis of prominent industry peers with a primary focus on key business financials, product portfolios, expansion strategies, and recent developments.
Detailed examination of drivers, restraints, key trends, and opportunities prevailing in the industry.
The study comprehensively covers the market across different segments.
Deep dive regional level analysis of the industry.
The global mpox treatment market can be customized further as per the requirement or any other market segment. Besides this, UMI understands that you may have your own business needs, hence feel free to connect with us to get a report that completely suits your requirements.
1. Market Introduction
2. Research Methodology or Assumption
3. Executive Summary
4. Market Dynamics
5. Global Mpox Treatment Market Revenue (USD Mn), 2022-2032F
6. Market Insights By Treatment Type
7. Market Insights By Route Of Administration
8. Market Insights By Distribution Channel
9. Market Insights By Region
10. Value Chain Analysis
11. Competitive Landscape
12. Company Profiles
13. Acronyms & Assumption
14. Annexure
Analyzing the historical market, estimating the current market, and forecasting the future market of the global mpox treatment market were the three major steps undertaken to create and analyze the adoption of mpox treatment in major regions globally. Exhaustive secondary research was conducted to collect the historical market numbers and estimate the current market size. Secondly, to validate these insights, numerous findings and assumptions were taken into consideration. Moreover, exhaustive primary interviews were also conducted, with industry experts across the value chain of the global Mpox treatment market. Post assumption and validation of market numbers through primary interviews, we employed a top-down/bottom-up approach to forecasting the complete market size. Thereafter, market breakdown and data triangulation methods were adopted to estimate and analyze the market size of segments and sub-segments of the industry. Detailed methodology is explained below:
Step 1: In-Depth Study of Secondary Sources:
A detailed secondary study was conducted to obtain the historical market size of the Mpox treatment market through company internal sources such as annual reports & financial statements, performance presentations, press releases, etc., and external sources including journals, news & articles, government publications, competitor publications, sector reports, third-party database, and other credible publications.
Step 2: Market Segmentation:
After obtaining the historical market size of the Mpox treatment market, we conducted a detailed secondary analysis to gather historical market insights and share for different segments & sub-segments for major regions. Major segments are included in the report as treatment type, route of administration, distribution channel, and regions. Further country-level analyses were conducted to evaluate the overall adoption of Mpox treatment in that region.
Step 3: Factor Analysis:
After acquiring the historical market size of different segments and sub-segments, we conducted a detailed factor analysis to estimate the current market size of the mpox treatment market. Further, we conducted factor analysis using dependent and independent variables such as treatment type, route of administration, distribution channel, and regions of the mpox treatment market. A thorough analysis was conducted for demand and supply-side scenarios considering top partnerships, mergers and acquisitions, business expansion, and product launches in the mpox treatment market across the globe.
Current Market Sizing: Based on actionable insights from the above 3 steps, we arrived at the current market size, key players in the global mpox treatment market, and market shares of the segments. All the required percentage shares split and market breakdowns were determined using the above-mentioned secondary approach and were verified through primary interviews.
Estimation & Forecasting: For market estimation and forecast, weights were assigned to different factors including drivers & trends, restraints, and opportunities available for the stakeholders. After analyzing these factors, relevant forecasting techniques i.e., the top-down/bottom-up approach were applied to arrive at the market forecast for 2032 for different segments and sub-segments across the major markets globally. The research methodology adopted to estimate the market size encompasses:
The industry’s market size, in terms of revenue (USD) and the adoption rate of the mpox treatment market across the major markets domestically.
All percentage shares, splits, and breakdowns of market segments and sub-segments.
Key players in the global mpox treatment market in terms of products offered. Also, the growth strategies adopted by these players to compete in the fast-growing market.
Primary Research: In-depth interviews were conducted with the Key Opinion Leaders (KOLs) including Top Level Executives (CXO/VPs, Sales Head, Marketing Head, Operational Head, Regional Head, Country Head, etc.) across major regions. Primary research findings were then summarized, and statistical analysis was performed to prove the stated hypothesis. Inputs from primary research were consolidated with secondary findings, hence turning information into actionable insights.
The data triangulation technique was employed to complete the overall market estimation and to arrive at precise statistical numbers for each segment and sub-segment of the global mpox treatment market. Data was split into several segments and sub-segments after studying various parameters and trends in the treatment type, route of administration, distribution channel, and regions of the global mpox treatment market.
The current & future market trends of the global mpox treatment market were pinpointed in the study. Investors can gain strategic insights to base their discretion for investments on the qualitative and quantitative analysis performed in the study. Current and future market trends determined the overall attractiveness of the market at a regional level, providing a platform for the industrial participant to exploit the untapped market to benefit from a first-mover advantage. Other quantitative goals of the studies include:
Analyze the current and forecast market size of the mpox treatment market in terms of value (USD). Also, analyze the current and forecast market size of different segments and sub-segments.
Segments in the study include areas of the treatment type, route of administration, distribution channel, and regions.
Define and analyze the regulatory framework for the mpox treatment
Analyze the value chain involved with the presence of various intermediaries, along with analyzing customer and competitor behaviors of the industry.
Analyze the current and forecast market size of the mpox treatment market for the major region.
Major countries of regions studied in the report include Asia Pacific, Europe, North America, and the Rest of the World
Company profiles of the mpox treatment market and the growth strategies adopted by the market players to sustain the fast-growing market.
Deep dive regional level analysis of the industry.
Q1: What is the mpox treatment market's current size and growth potential?
The mpox treatment market was valued at USD 1,025.46 million in 2023 and is expected to grow at a CAGR of 10.86% during the forecast period (2024-2032).
Q2: What are the driving factors for the growth of the mpox treatment market?
The rise of mpox cases, technological advancements, increasing focus on preventive measures, growing government support and funding, along with increasing research and development activities drive the mpox treatment market.
Q3: Which segment has the largest share of the mpox treatment market by route of administration?
The injectable segment has the largest share of the mpox treatment market by route of administration.
Q4: What are the major trends in the mpox treatment market?
Increased focus on preventive measures and growing research and development activities are the major trend in the mpox treatment market.
Q5: Which region will dominate the mpox treatment market?
North America dominated the market in 2023.
Customers who bought this item also bought
Antibiotic Resistance Market: Current Analysis and Forecast (2024-2032)
Emphasis on Disease Type (Urinary Tract Infections, Intra-Abdominal Infections, Blood Stream Infections, Clostridium Difficile Infections, And Others); Pathogen Type (Acinetobacter baumannii, Pseudomonas aeruginosa, Staphylococcus aureus, Streptococcus pneumoniae, and Others); Drug Class (Oxazolidinones, Lipoglycopeptides, Tetracyclines, and Others); and Region/Country
October 8, 2024
